NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock
Neuropace, Inc. (NPCE)
Company Research
Source: GlobeNewswire
MOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of its common stock. All of the shares are being offered by NeuroPace. In addition, NeuroPace intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. NeuroPace expects to use a substantial portion of the proceeds from the public offering to repurchase all of the shares held by NeuroPace’s significant stockholder, KCK Ltd., at a price per share equal to the price per share at which the underwriters will purchase shares of common stock from NeuroPace in the public offering. NeuroPace intends to use th
Show less
Read more
Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized EpilepsyBusiness Wire
- NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at UBS Group AG from $18.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- NeuroPace (NASDAQ:NPCE) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $20.00. They now have an "overweight" rating on the stock.MarketBeat
- NeuroPace (NASDAQ:NPCE) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
NPCE
Earnings
- 11/4/25 - Beat
NPCE
Sec Filings
- 12/15/25 - Form 144
- 12/4/25 - Form 4
- 12/1/25 - Form 4
- NPCE's page on the SEC website